With a €25 million ($27.7 million) series A commitment, an investor syndicate led by Forbion believes Dutch start-up Azafaros can develop a dual inhibitor of glycometabolic processes to treat lysosomal storage disorders, particularly those with...

Sue Desmond-Hellmann is stepping down after five years as CEO of the Bill & Melinda Gates Foundation . Before joining the foundation, she spent 14 years at Genentech Inc., where she helped develop cancer drugs Herceptin...

The widely anticipated release of negotiated additions to the National Reimbursement Drug List by China’s National Medical Insurance Administration came on Nov. 28, with Innovent’s Tyvyt the lone anti-PD-1 mAb to make the cut. In...

Solid Bio shares sag on news of latest clinical hold  FDA has placed a clinical hold on the Phase I/II IGNITE DMD study of gene therapy SGT-001 from Solid Biosciences Inc. (NASDAQ:SLDB) after one of...

David Eatwell will retire as CFO and EVP of Genmab A/S (CSE:GMAB; NASDAQ:GMAB) on Feb. 29. The cancer antibody therapy company will promote Anthony Pagano, SVP finance and corporate development, to CFO and EVP, effective...

Santhera and ReveraGen revealed Tuesday that glucocorticoid vamorolone showed improvement in timed function tests, the primary outcome for clinical efficacy, in a Phase IIa extension study in boys ages 4-7 with Duchenne muscular dystrophy. Santhera...

Galapagos’ pipeline partnership with Gilead sets the company up to become an independent leader of European biotech for years to come, and provides a template that other platform companies could follow. The July 14 deal...

Janssen’s ponesimod tops Aubagio in Phase III  The Janssen Pharmaceuticals unit of Johnson & Johnson (NYSE:JNJ) said it plans to submit NDAs to FDA and EMA this year after reporting ponesimod met the primary endpoint...

Six years after splitting from Abbott to pursue innovative drug development, AbbVie has taken a clear about-face, choosing a certain immediate revenue stream in its proposed acquisition of Allergan rather than opting for a riskier,...

LifeArc gets $1.3B for Keytruda royalties  U.K. medical research charity LifeArc sold an undisclosed portion of its royalties for Keytruda pembrolizumab to a subsidiary of the Canada Pension Plan Investment Board for $1.3 billion. LifeArc...